Meril Presents Successful LANDMARK RCT One-Year Results at Prestigious EuroPCR 2025
PRNewswire
Vapi (Gujarat) [India], May 22: Meril Life Sciences announced one-year results from its pivotal LANDMARK trial, presented during the prestigious Late-Breaking Trial session at EuroPCR 2025, one of the world's premier cardiology conferences held annually in Paris, France. The LANDMARK trial is the first randomized non-inferiority trial comparing the balloon-expandable Myval THV series with other contemporary balloon-expandable Sapien THV series and self-expandable Evolut THV series in patients with symptomatic severe aortic stenosis.
The Myval THV series demonstrated non-inferiority to contemporary THVs in terms of 1-year clinical efficacy composite endpoint (Myval THV Series: 13% vs. Contemporary THV: 13.1%, difference: -0.1%, one-sided 95% CI: 3.9%, Pnoninferiority < 0.0001).
Additionally, in the composite endpoint of clinical efficacy combined with QoL, outcomes were comparable (Myval THV Series: 19.5% vs. Contemporary THVs: 22.7%, difference: -3.2%, 95% CI: -9.2 to 2.9, P=0.33). Hemodynamic parameters including effective orifice area (EOA), mean pressure gradient (PG), and incidence of moderate or greater aortic regurgitation remained stable and similar across all treatment arms.
Survival rates were nearly identical (Myval THV Series: 92.8% vs. Contemporary THVs: 92.9%), and QoL improvements were comparable, reinforcing the overall safety and durability of the Myval THV series in everyday clinical use.
Professor Patri c k Serruys, Chairman and Study Director of the LANDMARK trial, said: "This trial reflects a new era in comparative valve research. The meticulous design and adherence to VARC-3 standards, including QoL endpoints, mark it as a pivotal study. The results of the LANDMARK trial represent a meaningful advancement for the global structural heart community--and most importantly, for patients receiving TAVI. The data not only validate the safety and efficacy of the Myval THV series, but also spotlight its adaptability to complex anatomies. This versatility is exactly what clinicians need to deliver precision care across a broad spectrum of patients."
Professor Andreas Baumbach, Global Principal Investigat or, said: "The LANDMARK trial represents a significant step forward in TAVI research. For the first time, we've benchmarked Myval against both balloon-expandable and self-expanding platforms in a rigorous randomized setting. The one-year results demonstrates that the new generation Myval THV series can match global standards in safety and efficacy."
Mr. Sanjeev Bhatt, Senior Vice President - Corporate Strategy at Meril, said: "The LANDMARK trial represents a significant milestone not just for Meril, but for the global TAVI community. The strong one-year results affirm the Myval THV series as a next-generation solution that delivers consistent safety, clinical efficacy, and improved quality of life across geographies. As the only head-to-head trial of its kind to include both balloon-expandable and self-expanding valves, it reinforces Myval THV series's versatility and real-world relevance for diverse patient anatomies and healthcare systems. At Meril, we are proud to contribute innovative, evidence-based technologies that are reshaping patient care and expanding access to advanced structural heart therapies worldwide."
The trial is designed to follow patients for a period of 10 years, aiming to generate long-term insights into clinical and echocardiographic outcomes, with a focus on valve durability and sustained performance.
About THE LANDMARK TRIAL:
The LANDMARK trial is the first randomized non-inferiority trial comparing the balloon-expandable Myval THV series with other contemporary balloon-expandable Sapien THV series and self-expandable Evolut THV series in patients with symptomatic severe aortic stenosis. The LANDMARK trial was a prospective, randomized, multicenter, open-label, non-inferiority trial involving 768 patients who underwent Transcatheter Aortic Valve Implantation (TAVI) for the treatment of aortic stenosis. The first patient was enrolled in the LANDMARK trial on 6 January 2021 and the last patient was enrolled on 5 December 2023. The trial included a total of 768 patients at 31 sites across 16 countries (Brazil, New Zealand, and some countries of Europe). The 30-day primary composite endpoints highlighting the safety and efficacy outcomes of the LANDMARK trial have been successfully published in The Lancet and EuroIntervention, two of the most prestigious peer-reviewed medical journals.
About Meril Life Sciences:
Meril is a global medical device company based in India, committed to advancing healthcare through innovation. With a strong focus on research and development, Meril delivers cutting-edge medtech solutions across more than 135 countries and has a robust presence through subsidiaries in the USA, Brazil, Europe, Asia, Africa, and Australia. Through partnerships, precision technology, and adherence to international quality standards, Meril is helping reshape the future of healthcare.
Media Contact: media@merillife.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hans India
2 days ago
- Hans India
Meril Launches MyClip, India's First Transcatheter-Edge-to-Edge Repair (TEER) System for Treatment of Severe Mitral Regurgitation
Meril Life Sciences, a leading global med-tech company, marked a significant milestone with the launch of MyClip, India's first Transcatheter Edge-To-Edge Repair (TEER) system, on June 14. The landmark Structural Heart Innovation event, held at Meril Academy, Vapi (Gujarat) from June 13–15, brought together over 150 Indian interventional cardiologists along with cardiac imaging expert and international stalwarts, including Prof. Ottavio Alfieri ('Father of mitral valve repair'), Prof. Francesco Maisano, and Prof. Agricola, joining global pioneers in edge-to-edge mitral valve repair. Meril is currently the world's leading TAVI group following the success of Myval THV and first Indian company to introduce a TEER system, placing the country firmly on the map as an innovator in transcatheter heart valve therapies (with both replacement and repair technology platforms). MyClip introduction demonstrates India's growing capabilities in structural heart solutions and reflects Meril's commitment to accessible cutting-edge cardiac care. MyClip TEER System is designed for patients suffering from severe Mitral Regurgitation (MR) who are at high surgical risk due to pre-existing issues like hypertension, diabetes, obesity, advanced age, physical frailty, enlarged or weak heart, and patients with kidney, lung and liver problems. MR, particularly if untreated, has a devastating mortality rate—over 50% of patients may not survive without timely intervention, and 1-year mortality can be as high as 57%. The MyClip TEER System enables precise closure of the mitral valve flaps, effectively preventing the backward flow of purified blood into the lungs. The procedure is minimally invasive, & takes approximately one hour, and allows patients to return home within 3–5 days. After discharge, patients can resume daily activities like walking and non-strenuous work within a short period post the procedure. According to the landmark COAPT Study published in the New England Journal of Medicine (NEJM), patients receiving device-based therapy for mitral regurgitation experienced significantly better outcomes compared to those receiving standard medical treatment. Within 24 months, the hospitalization rate for heart failure was reduced to 35.8% per patient-year in the device group, compared to 67.9% in the control group. Additionally, mortality within the same period was notably lower in the device group, at 29.1%, compared to 46.1% in the control group. Currently, approximately 150 TEER (Transcatheter Edge-to-Edge Repair) procedures are performed annually in India, with the majority of patients falling in the younger age group (30 – 60). These statistics bring to light a pressing need for early and effective intervention in younger demographics. The launch of MyClip TEER System marks a transformative moment for structural heart therapy in India. Transcatheter Edge-to-Edge Repair (TEER) therapy has shown significant success over traditional Guideline Directed Medical Therapy (GDMT). MyClip represents a major step forward in India's cardiovascular treatment landscape. In his inaugural speech, Sanjeev Bhatt, Senior Vice President of Corporate Strategy at Meril Life Sciences, said, 'In India, around 1.5 million people are known to have severe mitral regurgitation. Of these at least 1.2 million are post myocardial infarction (MI or a heart attack) or due to heart failure. Introduction of the MyClip TEER system marks a pivotal shift and we're witnessing early adoption. Meril's efforts in training cardiologists and building TEE-based imaging expertise are crucial steps in scaling this life-saving therapy across the country." 'With MyClip, Meril is reshaping the country's role in global medtech. This homegrown innovation is a testament to what Indian science, engineering, and clinical collaboration can achieve together. Meril's nationwide public awareness campaign #TreatmentZarooriHai is in full swing, with brand ambassador MS Dhoni, to educate patients and families about the life-saving value of timely intervention in mitral valve regurgitation,' Bhatt added. The two-day Structural Heart Innovation scientific program featured case demonstrations, interactive hands-on workshops, and the presentations leading Interventional Cardiologists and Echocardiologists. The event concluded with a call to build a sustainable M-TEER ecosystem in India, focused on accessibility, clinical excellence, and continuous innovation.
News18
11-06-2025
- News18
Beyond Blockages: Structural Heart Disease and the Rise of Minimally Invasive Solutions
Last Updated: A common example of structural heart disease is aortic valve stenosis, especially in patients over 60 years old. Heart disease is often associated with blocked arteries and heart attacks, but there's another lesser-known category of heart conditions that demands attention: structural heart disease. While coronary artery disease is defined by the narrowing or blockage of arteries that nourish the heart muscle, structural heart disease refers to abnormalities or defects in the heart's valves, walls, muscles, or chambers. These can be congenital—present from birth—or acquired over time due to aging, infections such as rheumatic fever, or degenerative changes. A common example of structural heart disease is aortic valve stenosis, especially in patients over 60 years old. This occurs when calcium deposits restrict and stiffen the aortic valve, making it harder for the heart to pump blood efficiently. Another congenital condition is the bicuspid aortic valve, where the valve has only two cusps instead of the usual three, leading to accelerated wear and valve failure, often in younger adults. Dr. Yugal Mishra, Chief of Clinical Services, Chairman of the Manipal Institute of Cardiac Sciences, and Chief Cardiovascular Surgeon at Manipal Hospital, Dwarka, New Delhi, shares everything you need to know: New symptoms of structural heart disease can include difficulty breathing, fatigue during everyday activities, chest discomfort, irregular heartbeats, or swelling in the limbs or abdomen. These may signal that the heart's valves or chambers are not functioning properly and require immediate medical attention. Surgical options such as valve repair or replacement remain effective, particularly in younger patients or those with minimal comorbidities. However, less invasive options have revolutionized care for older patients or those with additional kidney or lung complications. One such procedure is TAVR (Transcatheter Aortic Valve Replacement), also known as TAVI. In this approach, a prosthetic valve is inserted via catheter through an artery, avoiding the need for open-heart surgery. This minimally invasive method is particularly beneficial for patients with severely compromised health, offering restored heart function, faster recovery, and improved quality of life. Advanced therapies like TAVR offer renewed hope for living a healthier, more fulfilling life. If you or a loved one is experiencing recurring cardiac symptoms, it is advisable to consult a cardiologist. Early detection and timely intervention can make all the difference. As highlighted by the World Health Organization, cardiovascular disease (CVD)—including heart attacks and strokes—remains the leading cause of death worldwide. Alarmingly, many of these deaths are premature, especially among individuals under 70. Aortic stenosis (AS) is a prime example of a condition that can progress silently until it becomes critical. To further improve outcomes, the SMART trial evaluated various valve types used in TAVR procedures, enhancing treatment protocols, safety, and long-term success rates. For India to meet the growing burden of heart disease, a multi-faceted healthcare approach—combining early diagnostics and innovative treatments like TAVI—is essential to transform cardiac care and improve patient outcomes. News lifestyle » health-and-fitness Beyond Blockages: Structural Heart Disease and the Rise of Minimally Invasive Solutions
Fashion Value Chain
27-05-2025
- Fashion Value Chain
S.L. Raheja Hospital, Mumbai Completes 50 TAVI Procedures, Showcasing Excellence Minimally Invasive Heart Solutions
This milestone marks a major leap in delivering safer, faster, and more effective heart valve treatment for elderly and high-risk patients, setting high benchmarks for the hospitals Structural Heart Program In addition to its excellence in Cardiology, S.L. Raheja Hospital-a quaternary care center in Mumbai-offers advanced care in Oncology, Neurology, Orthopedics, Critical Care, Diabetology, and other specialties, ensuring comprehensive, patient-centered treatment Clinicians at the Department of Interventional Cardiology and Structural Heart Intervention at S.L. Raheja Hospital, Mahim – A Fortis Associate have successfully performed 50 Transcatheter Aortic Valve Implantation (TAVI) procedures – marking a significant milestone for cardiac care in the Mumbai region. This milestone puts S.L. Raheja Hospital, Mahim, at the forefront of cardiac care in Mumbai, with one of Mumbai's most advanced Structural Heart Programs. The milestone was achieved under the leadership of Dr. Haresh Mehta, Director – Interventional Cardiology and Structural Heart Interventions, along with Consultant – Interventional Cardiologists Dr. Kayan Siodia and Dr. Raghav Nagpal. (L-R) Dr Raghav Nagpal, Dr Haresh Mehta & Dr Kayan Siodia, Interventional Cardiology & Structural Heart Team at S.L. Raheja Hospital, Mumbai – A Fortis Associate TAVI is a minimally invasive procedure used to replace a narrowed Aortic Valve that fails to open properly, a condition known as Aortic Stenosis. It can be potentially life-changing for elderly and high-risk patients who are not suitable for open-heart surgery. Among the 50 procedures performed, the team has successfully navigated many complex cases – including bicuspid aortic valves (typically more challenging due to having two cusps instead of three) and extremely narrow femoral arteries, sometimes as small as 4.95 mm. In rare cases where femoral access was not feasible, the team has also performed trans carotid (neck-access) TAVIs with excellent results – demonstrating both technical expertise and adherence to standardized global best practices. Talking about the benefits of TAVI, Dr. Haresh Mehta, Director – Interventional Cardiology and Structural Heart Interventions, S.L. Raheja Hospital, Mahim – A Fortis Associate, said, 'Severe symptomatic Aortic Stenosis can limit a patient's life expectancy to just 2-to-5 years. Thus, TAVI, the procedure used to treat this condition, can bring about life-altering changes as it extends life, and also dramatically improves quality of life. Since it is minimally invasive, patients often feel relief within 24 hours of the procedure and are discharged within 48 hours – all without the need for open surgery, sutures, or any long recovery times. While TAVI is a key cardiac procedure, patients also benefit from a range of advanced treatments for other heart conditions, including pacemaker implantation, structural heart interventions, and coronary angioplasties.' Talking about the milestone, Dr. Kunal Punamiya, CEO, S.L. Raheja Hospital, Mahim – A Fortis Associate, said, 'This momentous achievement reflects our ongoing commitment to delivering cutting-edge cardiac interventions to those who need it the most. With this milestone, we continue to deliver world-class minimally invasive cardiac care that ensures improved outcomes, faster recovery, and enhanced quality of life. Our Structural Heart Program has been designed to provide cutting-edge cardiac therapies under one roof, which includes stenting and Angioplasty, Atherectomy, ICD and Pacemaker implantation, valve repair, and more. Additionally, we are equipped with a state-of-the-art Cath lab to support these advanced procedures.' This clinical achievement, like many others at S.L. Raheja Hospital Mumbai, reflect the hospital's unwavering commitment to compassionate care. It's milestones like these that allow the teams to keep pushing boundaries and touching lives – one patient at a time. About Fortis Healthcare Limited Fortis Healthcare Limited – an IHH Healthcare Berhad Company – is a leading integrated healthcare services provider in India. It is one of the largest healthcare organizations in the country with 27 healthcare facilities, ~4,750 operational beds (including O&M facilities), and over 400 diagnostics centers (including JVs). The Company is listed on the BSE Ltd and National Stock Exchange (NSE) of India. It draws strength from its partnership with a global major and parent company – IHH, to build upon its culture of world-class patient care and superlative clinical excellence. Fortis employs over 23,000 people (including Agilus Diagnostics Limited) who share its vision of becoming the world's most trusted healthcare network. Fortis offers a full spectrum of integrated healthcare services ranging from clinics to quaternary care facilities and a wide range of ancillary services.
